Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Astellas Pharma Inc. (ALPMY) Normalized Income after Taxes data is not available for the most recently reported fiscal quarter, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Normalized Income after Taxes |
-- |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$7.95B |
|
$2.20B |
|
$14.83B |
|
$22.78B |
|
$7.61B |
|
$3.86B |
|
$5.31B |
|
$12.92B |
|
$9.86B |
|
$-992.18M |
|
$9.86B |
|
-- |
|
| Cash Flow Statement Financials | |
$616.68M |
|
$-570.60M |
|
$-1.13B |
|
$2.22B |
|
$1.19B |
|
$-1.03B |
|
-- |
|
$-851.35M |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|